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Heparin was found to s|imulate the pllosohor>lation f histon¢ HI but not protamin¢ sul['~tte ¢at~lyx~d by Ca~*/phospholipid-dependenl protein 
kinas¢ (protein kinase C ~r Plg.C), Th~ dT~ct or heparin on histon¢ H 1 phosphorylation appeared to I~ due to an increase in phosphatidylserlne 
arl~nity ['or PKC activation in th~ presence: of"heparin, This etTect or hcparin was abolished when trypsinized, co[actor.independent. PKC was em- 
ployed to phosphorylate historic HI. These studi~s subtlest that h~parin acts at the regulatory domain of PKC, and emphasize the importance 
of' the nellative charlle in influencing the accessibility ol" the substrate to PKC action, 
Protein kinas~ C: Hcparin: Phosphoryh¢tion: Regulatory domain 
I, INTRODUCTION 
Protein kinase C (PKC) requires Ca ~" ,
phospholipids, and diacylglycerol for activation and 
translocation from cell eytosol to membranes. The 
three most commonly studied isozymes of PKC (types 
I, II and III) are closely related in structure and proper- 
ties. They contain regulatory and catalytic domains at 
the amino terminal half and at the arboxyl terminal 
half, respectively [1,2]. The former domain has been 
shown to contain a conserved region with features of a 
pseudosubstrate which has been proposed to maintain 
the enzyme in the inactive form [3]. It has been sug- 
gested that the binding of the allosteric ofactors to the 
regulatory domain of the enzyme r lieves the inhibition 
exerted at its catalytic domain II,2]. Furthermore, it 
appears that, in the membrane environment, polybasic 
structures may contribute to an attenuation of PKC ac- 
tivity [3], whereas the presence of negatively charged 
environment on the surface of the membrane may 
markedly influence the accessibility of the substrate to 
PKC action [13]. Thus, the nature of the substrate also 
plays an ~mportant role in the cofactor interaction with 
the regulatory domain. For example, it has been shown 
that phosphorylation f histone H1 catalyzed by PKC 
is significantly enhanced by phospholipids and diolein, 
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whereas that of protamine sulfate or the synthetic pep- 
tide for PKC is uninfluenced by these allosteric ofac- 
tots [1,2 4,5]. Analogous to this is tlie observation that 
partial proteolytic degradation of PKC results in the 
release of a fragment of the enzyme tlmt retains its 
catalytic activity but lacks the requirement for allosteric 
cofactors [1,2]. 
In the present communication we provide new 
evidence to suggest that charge properties at the 
regulatory domain of PKC play a major rote in reliev- 
ing the enzyme inhibition. For this, we utilized heparm 
which is a well known negatively charged molecule of 
considerable biological significance [6]. Heparin is a 
potent inhibitor of certain messenger-independent pro- 
tein kinase reactions [7,8]; however, we demonstrate 
here that PKC catalyzect phosphorylation f historic H i 
but not of protamine sulfate is markedly enhanced in 
the presence of heparin, This effect of heparin appears 
to be mediated via its interaction with phosphatidyl- 
serine binding to PKC and/or histone HI substrate. 
2. MATERIALS AND METHODS 
2.1, Animals 
Male Sprague-Dawley rats weighing 295-325 g, purchased from 
Harlan Spra~ue-Dawley Co,,Indianapolis, IN, were used as a source 
of ventral T)rostate as described 0reviously [9], 
2,2, Chemicals 
Lysine.rich histone HI was obtai~ed from Worthington 
Biochemical Corp., Freehold, N.I, Diolein, phosphatidylserine, pro- 
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taminf ~tdfal~, and ll¢l'hlrtn ~;¢re purchased from SiLtm~ Chemical T~bl¢ I 
wcr~ ,mppti~d by I)S Bio~'h~mi~eml, C' ~'~land, 0t-i, IZffed ~ h~l~rin oil ph~sphor)'lao~ f lit~loi'~¢ I l l  ~ltll pr~l~fltht~' 
~alf~l¢ eal~tlymd bP PKC 
2,~, Pur~fleu/im~ ~¢f PKC 
The procedure employed for p~rlial purifi~ation of r=tt ~'enlral pro, 
Slate PKC lso~ymcs wa~ a.s d¢,~¢ril~d pr¢~,-Iou~ty [I0, I l l .  T~-o lrt~hs 
isOfOrms of PKC (WP~ II ~r~.  and t?pe I l l  or . )  s~r~ hl~nlificd in 
I1~¢ proslatl¢ ~:ytosol [I l l . Cofwctor.tndependenl form ol' Ihe PKC 
~,,a~ prepared by Irealm~;'n! Of I|t¢ purified entymc ():S~Imll wilh 
Irxpsh'~ (I pi/ 'ml ['Or ~ rain al :~0"C1 a~t d~esirih,~d pr(viou,dy II=~l, 
Tryp~lni/,alio~ was lermi0~tl¢~;I by lhC ltddillo0 Of ~Oybcan trypsin i~, 
Hep¢~rin 
I'll, torte I'I I 
0.0 40?9 
0.2 4~0~ 
2,0 HI1) 
~I,0 90~7 
PI,~C ,tctivh~' Per¢<nl chance 
tnmol ~'~P~m¢.~hl 
0 
~I00 
* 122 
2.4, Det~rmh;ation of PA'C .¢tivit,v 
PKC =lctlvhy o~ays wtr¢ carried out at 30"C over a time ¢our~.e of 
O, 3, a~¢l 6 rain in a r~acdon medium consi~tinl~ of  10 m,M 
mal~rt¢~iam accm~e. 1,2 mM CaCh, 1 mM EG'FA, $0#tt/ml 
pbOHdLtathlylserine, 10/q~/ml diolein, 0.04% NP-40, 0.1 ittM 
I~J 'P lATP (spec, a~t, of 10g~.~(3O tlpm/pmol of ATP}. 20 mM Tris; 
HCI. pH 7..~, and I mtt,eml histone HI or protamin." sulfn|c as 
subszratc, in ¢~ final volume of O. !~ ml. The reaction wa~ initiated by 
the addition of [he enzyme und termhla|¢d a| tile Um¢ periods in, 
dieatcd PKC activity was e~pressctl as mttol ~:P Incorporated in the 
substrmellWmg or ~n~yme protein in zinc presence of 
Ca: "/phospholipids minus ~l~at in the absence of 
Ca"'/phosph~lipids [111, The experimental data presented are 
representative of type I I isoz),'me or PKC; Iiowcver, type III isozyme 
also ~avc similar resuhs, 
3, RESULTS AND DISCUSSION 
It is known that maximal histone HI phosphoryla- 
tton catalyzed by PKC requires the presence of 
Ca z+/phospholipids, whereas that of protamine sulfate 
can occur in the absence of these co factors, The regula- 
tton of substrate phosphorylation by anionic l pids 
(phosphatidylserine and diolein) is believed to relate to 
their charge properties in providing a favorable en- 
vtronment for interaction of PKC with the substrate 
[2,4,5]. Heparin, a naturally occurring negatively 
charged polymer with numerous biological activities 
[6], is known to influence certain protein kinase reac- 
tions such as those catalyzed by messenger-independent 
casein kinase II {see e.g. [7,8]). We therefore examined 
the effects of heparin on phosphorylation of histone 
HI and protamine sulfate catalyzed by purified PKC 
from rat ventral prostate cytosol. As shown in Table I, 
the presence of heparin (at 0,2-5 #g/ml) evoked a 
marked concentration-dependent stimulation of 
phosphorylation of histone H1 but not of protamine 
sulfate. Further, this observation was apparent for 
both the type II and type III isozymes of PKC (Fig. 1). 
Experiments were undertaken to determine if the 
stimulatory effect of heparin on historic phosphoryla- 
tion was mediated via its action at the catalytic or at the 
regulatory domain of PKC. It was observed that 
heparin stimulation of histone H1 phosphorylation was 
independent of the ATP concentration, suggesting that 
the effect of heparin was not due to its interaction with 
the catalytic domain of PKC. The apparent km for ATP 
Protamin¢ ~ul I'al¢ 
0,0 496 0 
:s,O :sOl ~. I 
Tl~e ;.~p~rlmcn|al details for 11'l~st.lf~lll¢lt! or pKr  .~,~dvhy rewards 
htsl~;~ne [q I anti prol;imine Its subslr;tles were as described in sC~elion 
2. Conccnlration of hcparin w~s varied n~, shown 
(10#~ observed by us) remained unchanged in the 
presence of 5#g/rnl of heparin in tile reaction, 
Likewise, the heparin stimulation of PKC activity oc- 
curred only in the presence of Ca 2. and heparin did not 
replace the Ca 2. requirement for the enzyme activity 
(data not shown), 
Allosteric cofactors such as diolein and 
phGsphatidylserine produce an activation of PKC 
(depending on the nature of the substrate) mrough ef- 
fects at the Ca 2"~ site (for diol¢in) or through modifica- 
tion of the regulatory domain via substrate-lipid 
complex formation for substrate interaction with the 
catalytic site, We therefore examined the effects of 
heparin on diolein and phosphatidylserine r quirement 
for PKC activity towards historic HI as substrate which 
2 3 4 
Fig, 1, Effect of heparin on phosphorylation of  histone H 1 catalyzed 
by type II and type I11 isozymes of PKC. Autoradiograra of gel 
electrophoreticalty separated hi,tone H 1 substrate after 
phosphorylation catalyzed by PKC lsozymes in the absence and 
presence of lxeparin (5/~g/ml) is shown, Lanes 1 and 2, PKC type II 
isozynae; lanes 3 and 4, PKC type III isozyme; lanes 1 and 3, control 
without heparin; lanes 2 and 4, with lteparin, Arrow indicates the 
position of histone HI. 
446 
Volume 2~2, number ~ F~S LETTERS M~X 1991 
T~bl~ tl 
l~rfe~;t of ll~pcwln ~rl PKC ~¢liVlt)" Iowltrd~ hlHol~¢ HI ~ varyinI~ 
~neenll'~lton, of pll~,~ph~,lldyl(~fme (PSI 
PS PKC a¢Iivily (nmol);P~mli#h) 
Conlrol,; Hop=trio (~/~ll/ml] 
O,0 9'/~ 164'~ ~- 69 
I0 ~691 "]45~ + 199 
~ 4"/10 IVIO~ ~ ~ 
~0 ~ I";"/ 9"/12 ~ ~1~ 
I00 8120 I C1054 * 24 
20~ 10392 122S6 .= 18 
. _ . . _  
• ~ Ch~n~l~ 
The ¢.~perlmeot=d d,=tall~ for mea)uremen~ of PKC ~etlvity w~r~ II~e 
~anle tt~ described In ~:tion ~. eseepl that pho~pl~atidyhc, rin¢ tPS) 
wa~ ~(Id¢fl at lh~ ¢on~'erttr~tion~ drown 
requires both of  these col'actors for maximal 
phosphoryladon. In results not shown, it was observed 
that at varied concentrations o f diolein, the stimulatory 
effect of heparin on phosphorylation f histone H I by 
PKC was essentially the same at all concentrations of  
diolein, i.e., it was enhanced by about 2-fold, as also 
observed in the absence of added diolein, This result 
suggested that heparin did not substi;ute for diolein at 
its site(s) of  action, It is generatly believed that diolein 
activates PKC by reducing the requirement for Can+; a 
lack of  effect of heparin on diolein requirement may be 
related to its lack of effect at the Ca z* site. 
Since activation of PHC with histone HI  as substrate 
also requires phosphatidylserine, the effect of  heparin 
was studied at varying concentrations of  
phosphatidylserine (Table II). Heparin stimulated the 
PKC activity towards histone HI in the absence of  
phosphatidylserine; however, in the presence of  
heparin, a maximal stimulation of PKC activity was 
obtained at significantly lower concentrations of 
phosphatidylserine (10/~g/ml phosphatidylserine plus 
5 ag/ml  of  heparin as compared with that at 100 ,~g/ml 
of  phosphatidylserine in  the absence of heparin). 
Kinetic analysis showed that heparm produced a 6-fold 
decrease in the apparent k,, for phosphatidylserine, and 
as expected, at relatively higher concentrations of  
phosphatidylserine the effect of heparin was at- 
tenuated. 
The above-described observations uggested that 
heparin-induced lowering of  the requirement for 
phosphatidylserine in the reaction may relate to an ef- 
fect of  heparin at the regulatory domain. To test this 
hypothesis, effect of heparin on trypsinized PKC was 
studied. Trypsinizatior, f PKC results in its cleavage 
into the catalytic ( -51 kDa) and regulatory fragments; 
however, the former behaves as a cofactor-independent 
PKC.  It is clear from the data in Table IIl that heparin 
stimulation of histone HI phosphorylation was 
abolished when trypsin-treated enzyme was used. 
"r~bl~ i11 
Eff¢~l o1" hcparln on Ih~ ~¢livtty or tryp~ini~(~d PKC t~w~rd~ hi~lon~ 
HI m~ ~ub'~lral~ 
P~Cldi,llon,'t PI~C ~'lJVlty (n11101)lPttll~llJh) 
No ~ofa¢lor~ Wish cof~¢lor~ ~PKC 
Imact ~n~ym~ 
Non© 200 3200 3000 
H~:p~)in (~ #l~/ml) 270 12'~0 7(]00 
Tr>'p~inixetl ~n~yme 
None ~100 ~1100 0 
Hcparin (5 +qVml) ~200 ~2(X~ 0 
PKC a~ltvily of the Intact and tryp~inlxed enxynte wa~ measured in 
the pre~en~:e o1' tile complete tts~a) ~;y~tem as tleseribed in ~¢¢tlon 2, 
es¢¢ pt ltat pho,'~phalidxherh~e, diolein, and Ca" were omztted when 
a~tty~ were ~;arrietl out [11111¢ ~tb$¢R'~¢ Or variou~ ¢ofaetors =~ ~hown, 
,3PKC rep~'e~en'tx the difrer¢.¢e of en~yz'ne activity Will~ or without 
¢ot'~elor~,l =tdded no(let each experJn)entnl eondhio~ 
It has been suggested that the interaction o f  a given 
substrate with various domains of  PKC may determ!ne 
the activity of the enzyme towards the particular 
substrate [2,5]. With regard to protamine sulfate as 
substrate, it is known that its phosphorylation catalyz- 
ed by PKC is not significantly enhanced in the presence 
o f  phosphatidylserine and diolein [2], giving rise to the 
proposal that protamine sulfate interacts trongly with 
PKC resulting in its aggregation in a binary mixture. 
This results in the presentation of  the substrate to the 
proximity of  the active sttes even without the cofactors. 
On the other hand, histone HI  phosphorylation by 
PKC may depend on its association with 
Ca2+/phosphatidylserine/diolein complex [2]. We pro- 
pose that hepann action on the regulatory domain o f  
PKC is  mediated largely via its lipid-binding domain. 
This is based on the following observations on heparin 
action: (l) it lowers the K,,,.~p for phosphatidylserine 
activation of PKC; (2) it has no effect on the activity 
of PKC towards protamine sulfate as substrate; (3) it 
has no effect on the kinase activity of  the cofactor- 
independent catalytic fragment of  PKC. Thus, heparin 
may alter the interaction of certain substrate/phospho- 
lipid complexes and contribute an additional negatively 
charged surface resulting in greater accessibility of the 
substrate to the enzyme. 
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